Articles related to Geriatrics

Long-term continuous monitoring for atrial fibrillation in older patients yielded an incidental diagnosis of sinus node dysfunction or atrioventricular block with bradycardia in 21% of patients over the age of 70. But the finding was not associated with any increased risk of syncope or sudden death.

In the ER, the patient was disoriented and appeared pale and diaphoretic. He initially complained of dizziness, shortness of breath, ringing in the ears, and feeling “weird.” Temperature and oxygen saturation were normal. BP was 182/112, and blood glucose was 152. Initial labs and studies showed no obvious cause for the patient’s problem. Follow Dr. Antonio Granfone through the differential and the ultimate discovery and correction of the cause.

Factors evaluated were diet, exercise, social integration, cognitive activity, smoking history, and alcohol use. Participants were categorized as favorable (4-6 positive factors), average (2–3 positive factors), and unfavorable (0–1 positive factor). The “favorable” group had a a slower decline in cognition even if they were APOE e4 carriers.

The development of new androgen receptor pathway inhibitors (ARPis) has resulted in a dramatic therapeutic paradigm change for the older adult illness of prostate cancer. Enzalutamide is one of the ARPis that is used more frequently. Darolutamide, apalutamide, and this medication were all first approved for the treatment of metastatic castrate-resistant prostate cancer, but they are now routinely used in the treatment of metastatic castrate-sensitive and non-metastatic castration-resistant prostate cancer. Only older persons with outstanding performance status are included in landmark phase III data demonstrating the effectiveness of ARPi in these patients. However, in the context of a narrative review, its function in older prostate cancer patients who are ineligible has to be investigated.

Reports on the Vaccine Safety Datalink flagged the need to investigate a potential increased risk those 65 years of age and older, for ischemic stroke in the first 21 days after receiving the bivalent Pfizer-BioNTech booster. FDA has parallel monitoring systems to confirm or fail to validate a safety signal. In this case, those other systems did not confirm the Vaccine Safety Datalink flag.

Yes, you read that right. According to a recent study in Scientific Reports, Chlamydia pneumoniae assaults the central nervous system by traveling up via the nose canal and into the brain. When the bacteria reach the brain, they encourage the production of amyloid beta protein, which is regarded to be a defining feature of dementia and Alzheimer’s disease.